Atria Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.2M Sell
27,342
-919
-3% -$429K 0.14% 149
2025
Q4
$12.8M Buy
28,261
+2,342
+9% +$1.01M 0.15% 139
2025
Q3
$10.2M Buy
25,919
+2,418
+10% +$1.01M 0.12% 185
2025
Q2
$10.5M Buy
23,501
+219
+0.9% +$101K 0.12% 181
2025
Q1
$11.3M Buy
23,282
+4,684
+25% +$2.18M 0.14% 160
2024
Q4
$7.49M Sell
18,598
-1,527
-8% -$708K 0.09% 246
2024
Q3
$9.36M Sell
20,125
-1,564
-7% -$751K 0.12% 204
2024
Q2
$10.2M Buy
21,689
+1,168
+6% +$507K 0.13% 168
2024
Q1
$8.58M Sell
20,521
-847
-4% -$358K 0.12% 196
2023
Q4
$8.69M Sell
21,368
-1,023
-5% -$378K 0.13% 182
2023
Q3
$7.79M Sell
22,391
-14
-0.1% -$4.9K 0.14% 180
2023
Q2
$7.88M Buy
22,405
+1,082
+5% +$365K 0.14% 168
2023
Q1
$6.72M Sell
21,323
-6,321
-23% -$1.9M 0.13% 196
2022
Q4
$7.98M Sell
27,644
-105
-0.4% -$32K 0.16% 153
2022
Q3
$8.03M Buy
27,749
+2,997
+12% +$862K 0.18% 138
2022
Q2
$6.97M Sell
24,752
-4,758
-16% -$1.27M 0.15% 172
2022
Q1
$7.7M Buy
29,510
+2,890
+11% +$686K 0.13% 180
2021
Q4
$5.85M Buy
26,620
+1,433
+6% +$279K 0.1% 234
2021
Q3
$4.57M Buy
25,187
+14,721
+141% +$2.87M 0.08% 279
2021
Q2
$2.11M Buy
10,466
+2,243
+27% +$469K 0.04% 478
2021
Q1
$1.77M Sell
8,223
-1,773
-18% -$389K 0.04% 491
2020
Q4
$2.36M Buy
9,996
+608
+6% +$140K 0.06% 376
2020
Q3
$2.56M Sell
9,388
-13,072
-58% -$3.61M 0.08% 278
2020
Q2
$6.52M Buy
22,460
+15,172
+208% +$4.11M 0.22% 110
2020
Q1
$1.73M Buy
7,288
+399
+6% +$91.5K 0.13% 153
2019
Q4
$1.51M Buy
6,889
+3,923
+132% +$794K 0.04% 398
2019
Q3
$502K Sell
2,966
-489
-14% -$86.5K 0.02% 576
2019
Q2
$625K Sell
3,455
-1,798
-34% -$314K 0.02% 518
2019
Q1
$966K Sell
5,253
-204
-4% -$37.7K 0.04% 369
2018
Q4
$904K Sell
5,457
-625
-10% -$108K 0.04% 326
2018
Q3
$1.17M Buy
6,082
+2,168
+55% +$386K 0.05% 356
2018
Q2
$665K Buy
3,914
+65
+2% +$10.1K 0.03% 485
2018
Q1
$627K Sell
3,849
-916
-19% -$150K 0.03% 463
2017
Q4
$714K Buy
4,765
+350
+8% +$51.8K 0.04% 409
2017
Q3
$671K Buy
4,415
+968
+28% +$146K 0.04% 395
2017
Q2
$444K Buy
+3,447
New +$415K 0.03% 455

Other funds holding VRTX

Atria Investments's VRTX Position: Q1 2026 in Review

Atria Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q1 2026, selling an estimated $429K and leaving 27,342 shares worth $12.2M. The position accounts for 0.14% of the portfolio, ranked #149.

Atria Investments first reported a position in VRTX in Q2 2017 and has held it in 36 quarters since. The position peaked at $12.8M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Atria Investments held 27,342 shares of Vertex Pharmaceuticals worth $12.2M as of Q1 2026.
  • Atria Investments sold 919 Vertex Pharmaceuticals shares in Q1 2026, an estimated $429K.
  • Vertex Pharmaceuticals made up 0.14% of Atria Investments's portfolio in Q1 2026, its #149 holding.
  • Atria Investments first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
  • Atria Investments's Vertex Pharmaceuticals position peaked at $12.8M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.